Search

Your search keyword '"Non-small cell lung cancer -- Genetic aspects -- Drug therapy"' showing total 4 results
Start Over Descriptor "Non-small cell lung cancer -- Genetic aspects -- Drug therapy" Journal mena report
4 results on '"Non-small cell lung cancer -- Genetic aspects -- Drug therapy"'

1. United States : Janssen Submits Application to U.S. FDA Seeking Approval of Amivantamab for the Treatment of Patients with Metastatic Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations

Subjects
United States. Food and Drug Administration, Johnson & Johnson, Chemotherapy, Small cell lung cancer -- Genetic aspects -- Drug therapy, Epidermal growth factors -- Genetic aspects, Pharmaceutical industry, Drug approval, Non-small cell lung cancer -- Genetic aspects -- Drug therapy, Cancer metastasis -- Genetic aspects -- Drug therapy, Business, international
Abstract

The Janssen Pharmaceutical Companies of Johnson & Johnson announced the submission of a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) seeking approval of amivantamab for [...]

Published
2020

2. United States : FDA Approves Genentechs Rozlytrek (entrectinib) for People With ROS1-Positive, Metastatic Non-Small Cell Lung Cancer and NTRK Gene Fusion-Positive Solid Tumors

Subjects
United States. Food and Drug Administration, Cancer genetics -- Genetic aspects -- Drug therapy, Genes, Small cell lung cancer -- Genetic aspects -- Drug therapy, Drug approval, Non-small cell lung cancer -- Genetic aspects -- Drug therapy, Cancer metastasis -- Genetic aspects -- Drug therapy, Phenols (Class of compounds), Tumors, Pediatrics, Morbidity, Tyrosine, Biological products industry, Child health, Lung cancer, Business, international
Abstract

Genentech, a member of the Roche Group, announced that the U.S. Food and Drug Administration (FDA) has approved Rozlytrek (entrectinib) for the treatment of adults with ROS1-positive, metastatic non-small cell [...]

Published
2019

3. Switzerland : FDA approves Roches Rozlytrek (entrectinib) for people with ROS1-positive, metastatic non-small cell lung cancer and NTRK gene fusion-positive solid tumours

Subjects
United States. Food and Drug Administration, Cancer genetics -- Genetic aspects -- Drug therapy, Genes, Small cell lung cancer -- Genetic aspects -- Drug therapy, Drug approval, Non-small cell lung cancer -- Genetic aspects -- Drug therapy, Cancer metastasis -- Genetic aspects -- Drug therapy, Morbidity, Tyrosine, Phenols (Class of compounds), Tumors, Pediatrics, Lung cancer, Business, international
Abstract

Roche announced that the US Food and Drug Administration (FDA) has approved Rozlytrek (entrectinib) for the treatment of adults with ROS1-positive, metastatic non-small cell lung cancer (NSCLC). The FDA has [...]

Published
2019

4. United States : TAGRISSO (AZD9291) approved by the US FDA for patients with EGFR T790M mutation-positive metastatic non-small cell lung cancer

Subjects
United States. Food and Drug Administration, AstraZeneca PLC, Small cell lung cancer -- Genetic aspects -- Drug therapy, Pharmaceutical industry, Non-small cell lung cancer -- Genetic aspects -- Drug therapy, Cancer metastasis -- Genetic aspects -- Drug therapy, Business, international
Abstract

AstraZeneca today announced that the US Food and Drug Administration (FDA) has approved TAGRISSO (AZD9291) 80mg once-daily tablets for the treatment of patients with metastatic epidermal growth factor receptor (EGFR) [...]

Published
2015

Catalog

Books, media, physical & digital resources
See catalog results